Indivior to appeal court verdict over Suboxone Film patents
Indivior, which specialises in addiction treatment drugs, intends to launch an appeal against a USDistrict Court for the District of Delaware verdict that could lead to rival companies selling a generic version of its Suboxone Film, a drug to treat opioid addiction.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
5 February 2019 Rivals of British pharmaceutical company Indivior will soon be able to sell generic versions of opioid addiction treatment Suboxone film following a ruling of the US Court of Appeals for the Federal Circuit.
22 November 2018 The US Court of Appeals for the Federal Circuit vacated a preliminary injunction against India-based Dr Reddy’s earlier this week, in a blow for addiction treatment drug producer Indivior.